PMID: 6110092Feb 28, 1981Paper

Nephrotoxicity of cyclosporin A in liver and kidney transplant patients

G B KlintmalmT E Starzl


In six of twelve orthotopic liver recipients nephrotoxicity was noted after 13-22 days of treatment with 16.3 + or - 2.9 (SEM) mg/kg per day of cyclosporin A (CyA). With a decrease in the daily CyA dose to 9.2 + or - 2.3 (SEM) mg/kg kidney function returned to normal. No hepatic rejections occurred on this lowered CyA dose. In 4 out of 66 kidney recipients a switch from a CyA dose of 5.2 - 10.7 mg/kg daily to azathioprine was done 4 - 8 months after transplant because of unsatisfactory kidney function, suspected to be due to nephrotoxicity. In three patients, this resulted in an improved graft function. A fourth transplant was lost to an irreversible rejection 13 days later. Thus CyA is nephrotoxic but this toxicity is easily reversed, even after many months of treatment, and the ease with which this complication can be managed suggests that nephrotoxicity should not diminish the high expectations that transplant surgeons have for CyA.


May 1, 1993·Transplant International : Official Journal of the European Society for Organ Transplantation·L JanssonA Andersson
Jan 1, 1996·Transplant International : Official Journal of the European Society for Organ Transplantation·S H JacobsonH E Wilczek
Sep 1, 1993·Digestive Diseases and Sciences·A J LoboA T Axon
Jun 1, 1986·World Journal of Surgery·B D KahanC T Van Buren
Jul 1, 1983·Biochemical Pharmacology·P H Whiting, J G Simpson
Sep 15, 1984·Biochemical Pharmacology·C CunninghamJ G Simpson
Mar 15, 1988·Biochemical Pharmacology·M MartinK Resch
Jan 1, 1988·British Journal of Plastic Surgery·C P EthridgeB M O'Brien
Apr 30, 1985·Clinica Chimica Acta; International Journal of Clinical Chemistry·J W van den BergS W Schalm
Mar 1, 1989·Toxicology Letters·G D NuytsM E De Broe
Mar 26, 2004·Transplantation Proceedings·C GraebW Land
Mar 26, 2004·Transplantation Proceedings·F Citterio
Jul 8, 1999·European Journal of Pharmacology·S KochiY Sawada
Jul 23, 1983·Lancet·E von Willebrand, P Häyry
Nov 2, 1985·Lancet·J I DuncanA W Thomson
Nov 1, 1985·Seminars in Liver Disease·S TodoT E Starzl
Aug 1, 1983·Seminars in Liver Disease·S IwatsukiT E Starzl
Oct 6, 1983·The New England Journal of Medicine·UNKNOWN Canadian Multicentre Transplant Study Group
Dec 1, 1981·Transplantation·G B KlintmalmT E Starzl
Apr 1, 1994·Clinical and Experimental Pharmacology & Physiology·A MartinJ A Whitworth
Jan 1, 1992·Journal of Clinical Periodontology·R A Seymour, D J Jacobs
Feb 1, 1986·Journal of Clinical Pathology·A J d'ArdenneP J Morris
Jan 16, 2016·BioMed Research International·Kristina L GoJae-Sung Kim
Jan 17, 1994·The American Journal of Medicine·R K Zetterman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.